Sensitivity and specificity of urinary neutrophil gelatinase-associated lipocalin and kidney injury molecule-1 for the diagnosis of renal cell carcinoma

American Journal of Nephrology

Volumn 34, Issue 5, 2011, Pages 391-398

  Morrissey, Jeremiah J ^a,c   London, Amy N ^a   Lambert, Matthew C ^b   Kharasch, Evan D ^a,c  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Renal Division   (United States)

^c USA   (United States)

Author keywords

Biomarker specificity; Kidney cancer; KIM 1; NGAL; Urinary biomarkers

Indexed keywords

KIDNEY INJURY MOLECULE 1; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; TUMOR MARKER;

ADULT; ARTICLE; CANCER SIZE; CANCER SURGERY; CLEAR CELL CARCINOMA; COHORT ANALYSIS; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE SEVERITY; FEMALE; HUMAN; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; NEPHRECTOMY; PAPILLARY CARCINOMA; PRIORITY JOURNAL; PROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY;

ACUTE-PHASE PROTEINS; CARCINOMA, RENAL CELL; FEMALE; HUMANS; KIDNEY NEOPLASMS; LIPOCALINS; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; PROSPECTIVE STUDIES; PROTO-ONCOGENE PROTEINS; RECEPTORS, VIRUS; SENSITIVITY AND SPECIFICITY;

EID: 80052594109     PISSN: 02508095     EISSN: 14219670     Source Type: Journal    
DOI: 10.1159/000330851     Document Type: Article

References (43)

1. Atkins MB, Bukowski RM, Escudier BJ, Figlin RA, Hudes GH, Kaelin WG Jr, Linehan WM, McDermott DF, Mier JW, Pedrosa I, et al: Innovations and challenges in renal cancer: summary statement from the Third Cambridge Conference. Cancer 2009; 115: 2247-2251.
2. NCI. 2011. National Cancer Institute. SEER (http://seer.cancer.gov/ statfacts/html/kidrp. html; accessed June 2011).
3. Biswas S, Eisen T: Immunotherapeutic strategies in kidney cancer-when TKIs are not enough. Nat Rev Clin Oncol 2009; 6: 478-487.
4. Lichtenfels R, Dressler SP, Zobawa M, Reck-tenwald CV, Ackermann A, Atkins D, Ker-sten M, Hesse A, Put tka mmer M, Lot tspeich F, et al: Systematic comparative protein expression profiling of clear cell renal cell carcinoma: a pilot study based on the separation of tissue specimens by two-dimensional gel electrophoresis. Mol Cell Proteomics 2009; 8: 2827-2842.
5. Cohen HT, McGovern FJ: Renal-cell carcinoma. N Engl J Med 2005; 353: 2477-2490. (Pubitemid 41770167)
6. Feldstein MS, Rhodes DJ, Parker AS, Orford RR, Castle EP: The haphazard approach to the early detection of asymptomatic renal cancer: results from a contemporary executive health programme. BJU Int 2009; 104: 53-56.
7. Figlin RA: Renal cell carcinoma: management of advanced disease. J Urol 1999; 161: 381-386, discussion 386-387.
8. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ: Cancer statistics, 2008. CA Ca ncer J Clin 2008; 58: 71-96.
9. Nogueira M, Kim HL: Molecular markers for predicting prognosis of renal cell carcinoma. Urol Oncol 2008; 26: 113-124. (Pubitemid 351288566)
10. Pantuck AJ, Zisman A, Belldegrun AS: The changing natural history of renal cell carcinoma. J Urol 2001; 166:1611-1623.
11. Levy DA, Slaton JW, Swanson DA, Dinney CP: Stage specific guidelines for surveillance after radical nephrectomy for local renal cell carcinoma. J Urol 1998; 159:1163-1167. (Pubitemid 28172785)
12. Gill IS, Aron M, Gervais DA, Jewett MA: Clinical practice. Small renal mass. N Engl J Med 2010; 362: 624-634.
13. Linehan JA, Nguyen MM: Kidney cancer: t he new landscape. Curr Opin Urol 2009; 19: 133-137.
14. Benway BM, Bhayani SB: Approach to the small renal mass: weighing treatment options. Curr Urol Rep 20 09; 10: 11-16.
15. Rini BI, Campbell SC, Escudier B: Renal cell carcinoma. Lancet 20 09; 373: 1119-1132.
16. Snow DC, Bhayani SB: Rapid communication: chronic renal insufficiency after lapa-roscopic partial nephrectomy and radical nephrectomy for pathologic t1a lesions. J En-dourol 2008; 22: 337-341. (Pubitemid 351301351)
17. Pettus JA, Jang TL, Thompson RH, Yossepowitch O, Kagiwada M, Russo P: Effect of baseline g lomerula r f iltration rate on surv iv-al in patients undergoing partial or radical nephrectomy for renal cortical tumors. Mayo Clin Proc 2008; 83:1101-1106.
18. Huang WC, Elkin EB, Levey AS, Jang TL, Russo P: Partial nephrectomy versus radical nephrectomy in patients with small renal tumors-is there a difference in mortality and cardiovascular outcomes? J Urol 2009; 181: 55-61, discussion 61-52.
19. Lucas SM, Nuss G, Stern J, Lotan Y, Saga-lowsky AI, Cadeddu JA, Raj GV: The screening for occult renal disease (SCORED) value is associated with a higher risk for having or developing chronic kidney disease in patients treated for small, unilateral renal masses. Cancer 2008; 113:2681-2686.
20. Miller DC, Hollingsworth JM, Hafez KS, Daignault S, Hollenbeck BK: Partial ne-phrectomy for small renal masses: an emerging quality of care concern? J Urol 2006; 175: 853-857, discussion 858. (Pubitemid 43199995)
21. Peycelon M, Hupertan V, Comperat E, Re-nard-Penna R, Vaessen C, Conort P, Bitker MO, Chartier-Kastler E, Richard F, Roupret M: Long-term outcomes after nephron sparing surgery for renal cell carcinoma larger than 4 cm. J Urol 2009; 181: 35-41.
22. Russo P, Huang W: The medical and oncological rationale for partial nephrectomy for the treatment of T1 renal cortical tumors. Urol Clin Nor th Am 2008; 35: 635-643, vii.
23. Devarajan P: Neutrophil gelatinase-associ-ated lipocalin (NGAL): a new marker of kidney disease. Scand J Clin Lab Invest Suppl 2008; 241: 89-94. (Pubitemid 351883665)
24. Mori K, Nakao K: Neutrophil gelatinase-as-sociated lipocalin as the real-time indicator of active kidney damage. Kidney Int 20 07; 71: 967-970. (Pubitemid 46741985)
25. Bachorzewska-Gajewska H, Malyszko J, Sit-niewska E, Malyszko JS, Dobrzycki S: Neutro-phil gelatinase-associated lipocalin (NGAL) correlations with cystatin C, serum creatinine and eGFR in patients with normal serum cre-atinine undergoing coronary angiography. Nephrol Dial Transplant 2007; 22:295-296. (Pubitemid 46050378)
26. Bolignano D, Coppolino G, Campo S, Aloisi C, Nicocia G, Frisina N, Buemi M: Urinary neutrophil gelatinase-associated lipocalin (NGAL) is associated with severity of renal disease in proteinuric patients. Nephrol Dial Tra nsplant 2008; 23: 414-416. (Pubitemid 351767366)
27. Goldstein SL, Devarajan P: Progression from acute kidney injury to chronic kidney disease: a pediatric perspective. Adv Chronic Kidney Dis 2008; 15:278-283. (Pubitemid 351833144)
28. Malyszko J, Bachorzewska-Gajewska H, Sit-niewska E, Malyszko JS, Poniatowski B, Do-brzycki S: Serum neutrophil gelatinase-asso-ciated lipocalinas a marker of renalfunction in non-diabetic patients with stage 2-4 chronic kidney disease. Ren Fail 2008; 30: 625-628.
29. Nickolas TL, Barasch J, Devarajan P: Bio-markers in acute and chronic kidney disease. Curr Opin Nephrol Hypertens 2008; 17:127-132. (Pubitemid 351253035)
30. Bonventre JV: Kidney injury molecule-1 (KIM-1): a specific and sensitive biomarker of kidney injury. Scand J Clin Lab Invest Suppl 20 08; 241: 78-83. (Pubitemid 351883663)
31. Ferguson MA, Vaidya VS, Bonventre JV: Bio-markers of nephrotoxic acute kidney injury. Toxicolog y 2008; 245: 18 2-19 3.
32. Vaidya VS, Ferguson MA, Bonventre JV: Bio-markers of acute kidney injury. Annu Rev Pharmacol Toxicol 2008; 48:463-493.
33. Friedl A, Stoesz SP, Buckley P, Gould MN: Neutrophil gelatinase- associated lipocalin in normal and neoplastic human tissues. Cell type-specific pattern of expression. Histo-chem J 1999; 31:433-441. (Pubitemid 29369301)
34. Barresi V, Ieni A, Bolignano D, Magno C, Bue-mi M, Barresi G: Neutrophil gelatinase-asso-ciated lipocalin immunoexpression in renal tumors: correlation with histotype and histo-logical grade. Oncol Rep 2010; 24:305-310.
35. Vila MR, Kaplan GG, Feigelstock D, Nadal M, Morote J, Porta R, Bellmunt J, Meseguer A: Hepatitis A virus receptor blocks cell differentiation and is overexpressed in clear cell renal cell carcinoma. Kidney Int 2004; 65: 1761-1773. (Pubitemid 38591024)
36. Han WK, Alinani A, Wu CL, Michaelson D, L oda M, McGovern FJ, T had han i R, Bonven-tre JV: Human kidney injury molecule-1 is a tissue and urinary tumor marker of renal cell carcinoma. J Am Soc Nephrol 2005; 16:1126-1134. (Pubitemid 41710324)
37. Lin F, Zhang PL, Yang XJ, Shi J, Blasick T, Han WK, Wang HL, Shen SS, Teh BT, Bon-ventre JV: Human kidney injury molecule-1 (hKIM-1): a useful immunohistochemical marker for diagnosing renal cell carcinoma and ovarian clear cell carcinoma. Am J Surg Pathol 2007; 31: 371-381. (Pubitemid 46673110)
38. Cockcroft DW, Gault MH: Prediction of cre-atinine clearance from serum creatinine. Nephron 1976; 16:31-41.
39. Porta C, Paglino C, De Amici M, Quaglini S, Sacchi L, Imarisio I, Canipari C: Predictive value of baseline serum vascular endothelial growth factor and neutrophil gelatinase-as-sociated l ipoc a l i n in adva nced k idney cancer patients receiving sunitinib. Kidney Int 2010; 77: 809-815.
40. McIlroy DR, Wagener G, Lee, HT: Neutro-phil gelatinase-associated lipocalin and acute kidney injury after cardiac surgery: the effect of baseline renal function on diagnostic performance. Clin J Am Soc Nephrol 2010; 5:211-219.
41. Morrissey JJ, London AN, Luo J, Kharasch ED: Urinary biomarkers for the early diagnosis of kidney cancer. Mayo Clinic Proc 2010; 85:413-421.
42. Tickoo SK, Gopalan A: Pathologic features of renal cortical tumors. Urol Clin North Am 2008; 35: 551-561, v.
43. Hu J, Verkman AS: Increased migration and metastatic potential of tumor cells expressing aquaporin water channels. FASEB J 2006; 20:1892-1894.